Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months

JAMA. 2017 Apr 25;317(16):1687-1688. doi: 10.1001/jama.2017.1840.

Authors

Gina Ogilvie¹, Chantal Sauvageau², Marc Dionne², Shelly McNeil³, Mel Krajden¹, Deborah Money¹, Simon Dobson¹

Affiliations

¹ University of British Columbia, Vancouver, British Columbia, Canada.
² Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, Quebec, Canada.
³ Dalhousie University, Halifax, Nova Scotia, Canada.

PMID: 28444267
DOI: 10.1001/jama.2017.1840

No abstract available

Publication types

Clinical Trial, Phase III
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Child
Female
Follow-Up Studies
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / administration & dosage*
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / immunology
Humans
Immunization Schedule
Immunogenicity, Vaccine*
Papillomavirus Infections / prevention & control
Time Factors

Substances

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18